Els G. Everaert

Brasschaat, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Recognising pituitary and thyroid dysfunction after craniospinal radiotherapy: an underrecognised mixed endocrine toxicity.

Recognising pituitary and thyroid dysfunction after craniospinal radiotherapy: an underrecognised mixed endocrine toxicity.

Journal: Endocrinology, diabetes & metabolism case reports

Published: September 24, 2025

Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?

Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?

Journal: Acta oncologica (Stockholm, Sweden)

Published: May 15, 2025

Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial.

Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial.

Journal: European urology oncology

Published: January 22, 2025

Author Correction: Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.

Author Correction: Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.

Journal: Nature medicine

Published: August 28, 2024

Evaluating pain management practices for cancer patients among health professionals in cancer and supportive/palliative care units: a Belgian survey.

Evaluating pain management practices for cancer patients among health professionals in cancer and supportive/palliative care units: a Belgian survey.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: March 10, 2024

Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.

Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.

Journal: Nature medicine

Published: January 13, 2024

Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study.

Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study.

Journal: BMC cancer

Published: August 30, 2018

TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer.

TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 18, 2018

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis.

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis.

Journal: Genome medicine

Published: May 11, 2018

Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.

Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.

Journal: The Prostate

Published: September 21, 2017

Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel?

Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel?

Journal: Clinical genitourinary cancer

Published: December 16, 2016

Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program.

Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program.

Journal: Urologic oncology

Published: October 25, 2015

Showing 1-12 of 12

Last Updated: 09/26/2026